Xiidra (lifitegrast ophthalmic solution) 5%
搜索文档
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
Globenewswire· 2026-01-05 20:00
Robert Dempsey Robert Dempsey, CEO of OKYO Pharma Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition with ...